Home » Authors » Aaron Lorenzo

Articles by Aaron Lorenzo

Transave Raises $12M For Work Targeting Diseases Of The Lung

Dec. 27, 2002

By Aaron Lorenzo

Valentis Licenses Technologies For Use In Schering Gene Efforts

Dec. 23, 2002

By Aaron Lorenzo

Endo Comes Up Short With One Product, Files NDA For Another

Dec. 23, 2002

By Aaron Lorenzo

Endo Comes Up Short With One Product, Files NDA For Another

Dec. 23, 2002

By Aaron Lorenzo

Valentis Licenses Technologies For Use In Schering Gene Efforts

Dec. 23, 2002

By Aaron Lorenzo

Neurocrine Signs Blockbuster Deal With Pfizer In Insomnia

Dec. 20, 2002

By Aaron Lorenzo

The folks at Neurocrine Biosciences Inc. should have slept well last night after potentially earning more than $400 million from the license of a late-stage compound to treat insomnia. (BioWorld Today)

Pharmacyclics Steps Back Up With Pivotal Study Of Xcytrin

Dec. 20, 2002

By Aaron Lorenzo

Pharmacyclics Steps Back Up With Pivotal Study Of Xcytrin

Dec. 20, 2002

By Aaron Lorenzo

Neurocrine Signs Blockbuster Deal With Pfizer In Insomnia

Dec. 20, 2002

By Aaron Lorenzo

The folks at Neurocrine Biosciences Inc. should have slept well last night after potentially earning more than $400 million from the license of a late-stage compound to treat insomnia. (BioWorld Today)

Angiogenix Raises $12M In Series C For Acclaim Product

Dec. 19, 2002

By Aaron Lorenzo

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...